《阿斯利康AstraZeneca（AZN）2024年年度报告「LSE」（英文版）（248页）.pdf》由会员分享，可在线阅读，更多相关《阿斯利康AstraZeneca（AZN）2024年年度报告「LSE」（英文版）（248页）.pdf（248页珍藏版）》请在三个皮匠报告上搜索。

1、What science can doAstraZeneca Annual Report and Form 20-F Information 2024 What science can doWe are a global,science-led,patient-focused pharmaceutical business,committed to excellence in the research,development and commercialisation of prescription medicines.We aim to transform the lives of pati

2、ents with improved outcomes and a better quality of life.Our SupplementsDetailed information on our Development Pipeline,Patent Expiries of Key Marketed Products and Risk.See our website, sustainability reportingOur sustainability reporting is prepared in line with the UK Companies Act 2006,sections

3、 414CA and 414CB.In anticipation of the EU Corporate Sustainability Reporting Directive(CSRD),we have started to incorporate selected disclosures in this Annual Report.Our key topics covered include material sustainability topics,which have been identified through our double materiality assessment,s

4、ee page 60 for more information.Front cover image:Oncology research and development(R&D)strategy.In Oncology R&D,we have a breadth of scientific platforms to attack cancer from multiple angles,and we are harnessing the power of combinations to drive even deeper responses and bring potential for cure

5、 to more patients.Use of terms:In this Annual Report,unless the context otherwise requires,AstraZeneca,the Group,we,us and our refer to AstraZeneca PLC and its consolidated entities.WelcomeStrategic ReportChairs Statement 2Chief Executive Officers Review 3What science can do 5AstraZeneca at a Glance

6、 6Healthcare in a Changing World 7Our Purpose,Values and Business Model 10Our Strategy and Key Performance Indicators 12Therapy Area Review 16Business Review 32Disclosure Statements 59Risk Overview 64Financial Review 67Financial StatementsPreparation of the Financial Statements and Directors Respons